Our Prescriptions for Prescription Drug Abuse
(Excerpted from GAO-15-471)
To minimize these risks, the DEA requires all drug distributors, pharmacies, and doctors that handle controlled substances to register with the agency. If the DEA sees anything suspicious, it can launch investigations and pursue fines, jail time, or other penalties. But does trying to keep prescription drugs out of the wrong hands make it harder for them to get into the right ones? When we surveyed businesses and practitioners registered with the DEA in 2014, over half reported changing certain practices due to the potential broader effects of DEA enforcement actions. For example, some distributors put stricter limits on the amount of drugs pharmacies could order, and some pharmacies reported delays in filling prescriptions to check for legitimate medical need. To help fix these issues, we recommended that the DEA take action to better balance patient access with abuse prevention. While the DEA reported steps it would take to follow our recommendations, we believe it needs to do more to fully address the problems we identified. Drug benefits can also be abused Like prescription drugs themselves, drug benefits can also be abused. We recently looked into Medicaid prescription drug fraud. Among other issues, we found indications that thousands of beneficiaries obtained $33 million worth of prescription drugs by doctor shopping—that is, visiting at least 5 doctors in order to receive prescriptions for noncontrolled substances. We also found other indications of fraud perpetrated by individuals and prescribers.(Excerpted from GAO-15-390)
To help the Centers for Medicare & Medicaid Services better fight fraud, we identified two potential controls that aren’t in CMS's current reporting requirements:- Lock-in programs for noncontrolled substances. Lock-in programs require suspect patients to use only one healthcare provider, one pharmacy, or both, in order to address doctor shopping. Why use them for noncontrolled substances? We found about 30 Medicaid beneficiaries with no record of having HIV who each got the HIV medication Atripla 12 or more times at a cost to Medicaid of at least $418,000.
- Prohibition of automatic refills. Ending automatic refills may help limit waste and save money by making it harder for patients to fill unnecessary prescriptions and stockpile drugs.
- Questions on the content of this post? Contact Linda Kohn at kohnl@gao.gov, George Scott at scottg@gao.gov, or Seto Bagdoyan at bagdoyans@gao.gov.
- Comments on GAO’s WatchBlog? Contact blog@gao.gov.
GAO's mission is to provide Congress with fact-based, nonpartisan information that can help improve federal government performance and ensure accountability for the benefit of the American people. GAO launched its WatchBlog in January, 2014, as part of its continuing effort to reach its audiences—Congress and the American people—where they are currently looking for information.
The blog format allows GAO to provide a little more context about its work than it can offer on its other social media platforms. Posts will tie GAO work to current events and the news; show how GAO’s work is affecting agencies or legislation; highlight reports, testimonies, and issue areas where GAO does work; and provide information about GAO itself, among other things.
Please send any feedback on GAO's WatchBlog to blog@gao.gov.